We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $4.94B
1-Year Est. Return 244.43%
This Fund
S&P 500
This Quarter Est. Return
+28.71%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.61B
AUM Growth
+$255M
Cap. Flow
+$47.3M
Cap. Flow %
1.31%
Top 10 Hldgs %
49.77%
Holding
131
New
18
Increased
36
Reduced
18
Closed
31

Top Buys

Rank Stock Value
1
MANE
Veradermics Inc
MANE
+$75.9M
2
CYTK icon
Cytokinetics
CYTK
+$39M
3
OLMA icon
Olema Pharmaceuticals
OLMA
+$32.4M
4
ERAS icon
Erasca
ERAS
+$29.4M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$23.3M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$76.1M
2
APLS
Apellis Pharmaceuticals
APLS
+$64.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$50.3M
4
RAPT
RAPT Therapeutics
RAPT
+$46.6M
5
ZYME icon
Zymeworks
ZYME
+$44.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.63%
2 Technology 3.69%
3 Communication Services 1.71%
4 Consumer Discretionary 0.77%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLN
51
Silence Therapeutics
SLN
$834M
$15.3M 0.43%
2,911,438
– –
MSFT icon
52
Microsoft
MSFT
$3.81T
$15.3M 0.42%
41,380
+26,380
+176% +$11M
MNPR icon
53
Monopar Therapeutics
MNPR
$751M
$14.8M 0.41%
270,118
+57,820
+27% +$3.49M
TSM icon
54
TSMC
TSM
$2.17T
$14.3M 0.4%
42,200
+14,500
+52% +$4.99M
SION
55
Sionna Therapeutics
SION
$265M
$12M 0.33%
300,000
– –
NBIS
56
Nebius Group N.V.
NBIS
$56.9B
$11.8M 0.33%
113,614
+37,396
+49% +$3.73M
RZLT icon
57
Rezolute
RZLT
$445M
$10.2M 0.28%
+3,328,287
New +$9.99M
IKT icon
58
Inhibikase Therapeutics
IKT
$336M
$9.83M 0.27%
5,850,000
– –
AMZN icon
59
Amazon
AMZN
$2.87T
$9.71M 0.27%
46,641
-4,859
-9% -$1.07M
GENB
60
Generate Biomedicines
GENB
$1.97B
$9.2M 0.26%
+736,104
New +$8.99M
MPLT
61
MapLight Therapeutics
MPLT
$584M
$9.15M 0.25%
450,000
– –
NOW icon
62
ServiceNow
NOW
$150B
$9.11M 0.25%
87,090
+51,460
+144% +$6.05M
CRWD icon
63
CrowdStrike
CRWD
$224B
$9.01M 0.25%
92,280
+26,280
+40% +$2.78M
PDD icon
64
Pinduoduo
PDD
$122B
$8.52M 0.24%
83,401
+20,000
+32% +$2.1M
TSLA icon
65
Tesla
TSLA
$1.38T
$7.99M 0.22%
21,500
+20,000
+1,333% +$8.24M
NBP
66
NovaBridge Biosciences American Depositary Shares
NBP
$213M
$7.38M 0.2%
3,000,000
– –
BCYC
67
Bicycle Therapeutics
BCYC
$294M
$7.24M 0.2%
1,560,882
-451,870
-22% -$2.58M
WHWK
68
Whitehawk Therapeutics
WHWK
$263M
$7.18M 0.2%
2,082,000
– –
TENX icon
69
Tenax Therapeutics
TENX
$79.7M
$6.83M 0.19%
427,141
– –
VTVT icon
70
vTv Therapeutics
VTVT
$128M
$6.46M 0.18%
163,000
– –
DDOG icon
71
Datadog
DDOG
$85.1B
$6.41M 0.18%
54,300
+17,875
+49% +$2.21M
FROG icon
72
JFrog
FROG
$12.2B
$6.05M 0.17%
128,816
+35,200
+38% +$1.73M
DT icon
73
Dynatrace
DT
$15.5B
$5.55M 0.15%
150,000
+34,771
+30% +$1.33M
WK icon
74
Workiva
WK
$4.31B
$5.52M 0.15%
92,500
+13,377
+17% +$933K
ABSI icon
75
Absci
ABSI
$1.49B
$5.4M 0.15%
+1,800,000
New +$5.21M
1 2
3
4 5

Similar funds

AAS
Ameritas Advisory Services Lincoln, Nebraska $4.96B AUM 27.52% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
FC
Freemont Capital Singapore $4.9B AUM 11.61% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $4.99B AUM 23.08% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Siren LLC's Q1 2026 Portfolio in Review

As of Q1 2026, Siren LLC held 131 positions worth $3.61B, up 7.6% from $3.35B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Siren LLC's Q1 2026 filing shows 18 new, 36 increased, 18 reduced and 31 closed positions. Its largest new stake was Veradermics Inc: 1,505,374 shares worth $95.1M. The largest sale was Centessa Pharmaceuticals, an estimated $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q1 2026 buy was Veradermics Inc: 1,505,374 shares worth $95.1M.
  • Siren LLC added most to Olema Pharmaceuticals in Q1 2026, an estimated $32.4M increase.
  • Siren LLC's biggest Q1 2026 reduction was Centessa Pharmaceuticals, cutting an estimated $76.1M.
  • Siren LLC fully exited Apellis Pharmaceuticals in Q1 2026, selling an estimated $64.8M.
  • Siren LLC's ten largest holdings make up 50% of its $3.61B portfolio in Q1 2026.
  • Siren LLC opened 18 new positions and closed 31 in Q1 2026.
  • Siren LLC's portfolio value rose 7.6% quarter-over-quarter to $3.61B.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.